Ken Griffin Innate Pharma Sa Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Innate Pharma Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 23,527 shares of IPHA stock, worth $52,935. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,527Holding current value
$52,935% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding IPHA
# of Institutions
9Shares Held
242KCall Options Held
0Put Options Held
0-
Optiver Holding B.V. Amsterdam, P787.4KShares$196,5420.0% of portfolio
-
Exchange Traded Concepts, LLC86.2KShares$194,0330.0% of portfolio
-
Morgan Stanley New York, NY43.5KShares$97,9290.0% of portfolio
-
Barclays PLC London, X0412Shares$9270.0% of portfolio
-
Ubs Group Ag297Shares$6680.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $180M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...